LGND
Ligand Pharmaceuticals IncCompany with tickers: LGND, LGNDZ, LGNXZ, LGNYZ, LGNZZ
CIK
886163
CUSIP
53220K504
Shares Outstanding
20,041,061
Website
https://www.ligand.com
Investor Relations
https://investor.ligand.com/overview/default.aspx
13F Activity (30d)
35 filings
12 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $51,722,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $2,148,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Operating Income | $17,368,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Net Income | $-13,345,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Basic) | $-0.67 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Diluted) | $-0.67 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Development And Licensing Of Biopharmaceutical Assets | $196,245,000 | $131,314,000 | $167,133,000 | $268,087,000 |
By Product & Service (USD)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|
| Royalty | $33,796,000 | $48,927,000 | $72,912,000 | $84,959,000 | $108,773,000 | $161,001,000 |
| Intangible Royalty Assets | — | — | $72,527,000 | $83,910,000 | $95,329,000 | $132,534,000 |
| Contract Revenue And Income | — | — | — | $17,983,000 | $27,477,000 | $66,873,000 |
| Contract Revenue | $19,807,000 | $28,367,000 | $18,838,000 | $17,983,000 | $27,477,000 | $66,873,000 |
| Income From Divestiture Transactions | — | — | — | $0 | $0 | $53,072,000 |
| Material Sales Captisol Core | $24,566,000 | $23,423,000 | $16,429,000 | $28,372,000 | $30,883,000 | $40,213,000 |
| Material Sales Captisol | $109,959,000 | $164,250,000 | $104,495,000 | $28,372,000 | $30,883,000 | $40,213,000 |
| Royalty Kyprolis | $25,164,000 | $27,472,000 | $30,116,000 | $35,640,000 | $38,377,000 | $35,534,000 |
| Filspari | — | — | $0 | $2,655,000 | $12,179,000 | $31,971,000 |
| Financial Royalty Assets | — | — | $385,000 | $1,049,000 | $13,444,000 | $28,467,000 |
| QARZIBA | — | — | — | $0 | $11,120,000 | $23,739,000 |
| Royalty Rylaze | $0 | $2,420,000 | $8,796,000 | $13,520,000 | $13,743,000 | $13,350,000 |
| Royalty Other | $2,255,000 | $3,696,000 | $6,550,000 | $6,760,000 | $7,486,000 | $10,366,000 |
| Capvaxive | — | — | — | $0 | $626,000 | $10,059,000 |
| Ohtuvayre | — | — | — | $0 | $833,000 | $9,760,000 |
| Royalty Teriparatide Injection | $0 | $5,260,000 | $15,785,000 | $11,061,000 | $8,221,000 | $8,148,000 |
| Vaxneuvance | — | — | $1,083,000 | $4,062,000 | $5,184,000 | $7,403,000 |
| License Fees | $119,000 | $634,000 | $0 | $0 | $1,944,000 | $6,988,000 |
| Service | $9,330,000 | $3,737,000 | $18,838,000 | $17,983,000 | $25,533,000 | $6,813,000 |
| Royalty Evomela | $6,377,000 | $10,079,000 | $10,197,000 | $10,212,000 | $8,680,000 | $5,943,000 |
| Financial Royalty Other | — | — | — | $1,049,000 | $2,324,000 | $4,728,000 |
| Contract Revenue And Other Income | — | — | $18,838,000 | $17,983,000 | $27,477,000 | — |
| License Fees Milestones And Other Product Other | $5,141,000 | $6,412,000 | $6,107,000 | $1,400,000 | — | — |
| Material Sales Captisol COVID | $85,393,000 | $140,827,000 | $88,066,000 | $0 | $0 | — |
| Milestone | $5,217,000 | $17,584,000 | $9,150,000 | $16,800,000 | — | — |